Phase III REMIX-1 and REMIX-2 data will highlight remibrutinib’s impact on early symptom relief and sustained disease control in chronic spontaneous urticaria. These analyses follow the recent FDA nod and aim to support label expansions and market uptake. Novartis will showcase five key abstracts on remibrutinib at the AAAAI Annual Meeting in Philadelphia from February 27 to March 2, 2026. The oral Bruton's tyrosine kinase inhibitor Rhapsido® has already gained FDA approval for chronic spontaneous urticaria and is now being studied for broader immune indications. For the first time, Novartis will present Phase II data on remibrutinib’s efficacy in IgE-mediated peanut allergy during an oral session. Positive findings have prompted plans for a Phase III peanut allergy program slated to begin in 2026, targeting a large unmet therapeutic need. Global regulatory reviews for remibrutinib in CSU are in progress in the European Union and Japan. The company completed an FDA submission in Q4 2025 for symptomatic dermographism and reported positive topline results in two additional CIndU arms, while full data will be filed with authorities in coming months.